These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38139333)

  • 21. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
    Rasmussen MH; Jensen NF; Tarpgaard LS; Qvortrup C; Rømer MU; Stenvang J; Hansen TP; Christensen LL; Lindebjerg J; Hansen F; Jensen BV; Hansen TF; Pfeiffer P; Brünner N; Ørntoft TF; Andersen CL
    Mol Oncol; 2013 Jun; 7(3):637-46. PubMed ID: 23506979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
    Xu R; Yin J; Zhang Y; Zhang S
    J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
    Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
    Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells.
    Chiu SJ; Chao JI; Lee YJ; Hsu TS
    Toxicol Lett; 2008 Jun; 179(2):63-70. PubMed ID: 18499365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomic Analysis of miR-195 and miR-497 Replacement Reveals Potential Candidates that Increase Sensitivity to Oxaliplatin in MSI/P53wt Colorectal Cancer Cells.
    Poel D; Boyd LNC; Beekhof R; Schelfhorst T; Pham TV; Piersma SR; Knol JC; Jimenez CR; Verheul HMW; Buffart TE
    Cells; 2019 Sep; 8(9):. PubMed ID: 31546954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Supramolecular Chemotherapy: Carboxylated Pillar[6]arene for Decreasing Cytotoxicity of Oxaliplatin to Normal Cells and Improving Its Anticancer Bioactivity Against Colorectal Cancer.
    Hao Q; Chen Y; Huang Z; Xu JF; Sun Z; Zhang X
    ACS Appl Mater Interfaces; 2018 Feb; 10(6):5365-5372. PubMed ID: 29355009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
    Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
    BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116.
    Kukcinaviciute E; Jonusiene V; Sasnauskiene A; Dabkeviciene D; Eidenaite E; Laurinavicius A
    J Cell Biochem; 2018 Jul; 119(7):5913-5920. PubMed ID: 29637602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.
    Narvi E; Vaparanta K; Karrila A; Chakroborty D; Knuutila S; Pulliainen A; Sundvall M; Elenius K
    Sci Rep; 2018 Nov; 8(1):16579. PubMed ID: 30410004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hwang-Heuk-San induces apoptosis in HCT116 human colorectal cancer cells through the ROS-mediated activation of caspases and the inactivation of the PI3K/Akt signaling pathway.
    Lee MH; Hong SH; Park C; Kim GY; Leem SH; Choi SH; Keum YS; Hyun JW; Kwon TK; Hong SH; Choi YH
    Oncol Rep; 2016 Jul; 36(1):205-14. PubMed ID: 27221553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
    Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells.
    Allen WL; McLean EG; Boyer J; McCulla A; Wilson PM; Coyle V; Longley DB; Casero RA; Johnston PG
    Mol Cancer Ther; 2007 Jan; 6(1):128-37. PubMed ID: 17237273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.
    Park J; Lee GE; An HJ; Lee CJ; Cho ES; Kang HC; Lee JY; Lee HS; Choi JS; Kim DJ; Choi JS; Cho YY
    Arch Pharm Res; 2021 Dec; 44(12):1091-1108. PubMed ID: 34750753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo.
    Howells LM; Sale S; Sriramareddy SN; Irving GR; Jones DJ; Ottley CJ; Pearson DG; Mann CD; Manson MM; Berry DP; Gescher A; Steward WP; Brown K
    Int J Cancer; 2011 Jul; 129(2):476-86. PubMed ID: 20839263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxali(IV)Fluors: Fluorescence Responsive Oxaliplatin(IV) Complexes Identify a Hypoxia-Dependent Reduction in Cancer Cells.
    Boulet MHC; Bolland HR; Hammond EM; Sedgwick AC
    J Am Chem Soc; 2023 Jun; 145(24):12998-13002. PubMed ID: 37283248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
    Huang C; Zhou T; Ma L; Zhao S
    Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines.
    Yang C; Zhou Q; Li M; Tong X; Sun J; Qing Y; Sun L; Yang X; Hu X; Jiang J; Yan X; He L; Wan C
    Sci Rep; 2016 Sep; 6():33078. PubMed ID: 27609465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells.
    Bose D; Zimmerman LJ; Pierobon M; Petricoin E; Tozzi F; Parikh A; Fan F; Dallas N; Xia L; Gaur P; Samuel S; Liebler DC; Ellis LM
    Br J Cancer; 2011 Nov; 105(11):1759-67. PubMed ID: 22045189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.
    Wei TT; Lin YT; Tang SP; Luo CK; Tsai CT; Shun CT; Chen CC
    Oncogene; 2020 Jan; 39(2):414-427. PubMed ID: 31477841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.